Navigation Links
Vion Reports 2007 Third Quarter and Nine-Month Results
Date:11/7/2007

Company Updates Status of Cloretazine(R) (VNP40101M) Clinical Trials in AML

NEW HAVEN, Conn., Nov. 7 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq Capital Market: VION) today announced results for the three-month and nine-month periods ended September 30, 2007.

The Company reported a net loss of $9.0 million, or $0.13 per share, for the three-month period ended September 30, 2007, compared to a net loss of $6.3 million, or $0.10 per share, for the same period in 2006. Weighted- average common shares outstanding for the three months ended September 30, 2007 and 2006 were 67.7 million and 66.2 million, respectively.

For the nine-month period ended September 30, 2007, the net loss was $25.8 million, or $0.39 per share, compared to a net loss of $19.2 million, or $0.29 per share, for the same period in 2006. Weighted-average common shares outstanding for the nine months ended September 30, 2007 and 2006 were 66.8 million and 66.2 million, respectively.

Total operating expenses were $8.6 million and $6.8 million for the three months ended September 30, 2007 and 2006, respectively, and $25.1 million and $20.8 million for the nine months ended September 30, 2007 and 2006, respectively.

In the quarter, the increase in operating expenses was due to higher total research and development expenses resulting from: (i) late-stage clinical development of Cloretazine(R) (VNP40101M), including additional personnel, drug production costs and other costs in support of a potential registration filing and (ii) stock-based compensation expense. In addition, marketing, general and administrative expenses were higher than the prior year quarter, primarily due to increased medical advisory board meetings and stock-based compensation expense.

In the nine-month period, the increase in operating expenses was due to higher total research and development expenses resulting from: (i) late-stage clinical development of Cloretazine(R) (VNP40101M), including additional personnel, drug production costs and other costs in support of a potential registration filing; (ii) stock-based compensation expense; and (iii) a gift to support research projects at a Yale University laboratory, partially offset by lower spending on preclinical drug production. In addition, marketing, general and administrative expenses were higher than the prior year period, primarily due to increased stock-based compensation expense, medical advisory board meetings and patent fees.

The Company reported $1.2 million and $3.4 million of stock-based compensation expense in the three-month and nine-month periods ended September 30, 2007, respectively, as compared to $413,000 and $1.4 million for the comparable 2006 periods.

The Company reported $3.7 million in interest expense for the nine months ended September 30, 2007 related to its private placement in February 2007 of convertible debt and warrants. There was no interest expense in 2006. Interest income increased from $1.6 million for the nine-month period ended September 30, 2006 to $2.6 million for the comparable 2007 period based on higher invested balances and higher interest rates in 2007.

The Company reported ending the quarter with $68.0 million in cash and cash equivalents. Based on its current operating plan, the Company reported that it had funds to operate the Company into the third quarter of 2009 excluding any expenses for commercialization of Cloretazine(R) (VNP40101M) in the United States. If the Company does commercialize Cloretazine(R) (VNP40101M) in the United States on its own, it would have to raise additional capital.

In August, the Company announced that it had completed the initial target accrual of 85 patients for its pivotal Phase II trial of Cloretazine(R) (VNP40101M) as a single agent in elderly de novo poor-risk acute myelogenous leukemia (AML). Recent FDA/ICH guidance recommends that an electrocardiograph evaluation (QT/QTc) study be included in the clinical development of all new drugs. Therefore, the trial continues to accrue patients at a few sites in the United States in a cardiac sub-study.

Alan Kessman, Chief Executive Officer, commented, "We will be presenting preliminary information from our pivotal Phase II trial of Cloretazine(R) (VNP40101M) as a single agent in elderly de novo poor-risk AML at the American Society of Hematology Meeting in December." He concluded, "Our objective remains to file a New Drug Application (NDA) for Cloretazine(R) (VNP40101M) with the FDA in 2008 based on this trial. We are already working on preparing the appropriate documentation for the NDA."

With regard to the pivotal Phase III trial in relapsed AML of Cloretazine(R) (VNP40101M) in combination with cytarabine which is on clinical hold, the Company announced that discussions with the data safety monitoring board (DSMB) related to the findings of a medical and safety review of the trial had been completed. The next step of the process is to discuss the conclusions with the regulatory authorities. There can be no assurance that these discussions will result in a continuation of the Phase III trial or what the timing of any such continuation might be.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer, with temozolomide in brain tumors, and with stem cell transplant in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended June 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203) 498-4210

--Financial Statements Follow--

VION PHARMACEUTICALS, INC.

(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

(In thousands, except per share 2007 2006 2007 2006

data)

Technology license fee revenue $6 $6 $16 $16

Operating expenses:

Clinical trials 3,490 3,285 10,781 9,983

Other research and development 2,786 2,336 7,898 6,514

Total research and

development 6,276 5,621 18,679 16,497

Marketing, general and

administrative 2,279 1,216 6,387 4,260

Total operating expenses 8,555 6,837 25,066 20,757

Loss from operations (8,549) (6,831) (25,050) (20,741)

Interest income 938 502 2,603 1,560

Interest expense (1,423) -- (3,652) --

Other expense, net -- (3) (4) (31)

Loss before income taxes (9,034) (6,332) (26,103) (19,212)

Income tax provision (benefit) 3 10 (269) 34

Net loss $(9,037) $(6,342) $(25,834) $(19,246)

Basic and diluted loss per share $(0.13) $(0.10) $(0.39) $(0.29)

Weighted-average number of shares

of common stock outstanding 67,743 66,231 66,828 66,167

CONDENSED CONSOLIDATED BALANCE SHEET DATA

(Unaudited)

Sep. 30, Dec. 31,

(In thousands) 2007 2006

Cash and cash equivalents $68,011 $30,914

Total assets 70,091 31,856

Convertible senior notes 54,017 --

Total liabilities 61,831 6,402

Shareholders' equity 8,260 25,454


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
Breaking Medicine Technology: